Eli M. Wallace Receives Stock Award at BridgeBio Oncology Therapeutics Inc (BBOT) — SEC Form 4, Jan 06, 2026

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Eli M. Wallace

CEO

TXN 2026-01-01 · FILED 2026-01-06

Filing Lag 3 business days late vs 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

BridgeBio Oncology Therapeutics Inc

BBOT CIK 0001869105

Reporting Owner

Name	Relationship
Eli M. Wallace CIK 0001776352	Director CEO

Eli M. Wallace at BridgeBio Oncology Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at BridgeBio Oncology Therapeutics Inc

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)F1	$12.52	2026-01-01	A - Award/Grant	1,114,400 A	$0.00	2035-12-31	1,114,400 Common Stock	Direct

Footnotes (1)

F1: 69,650 of the shares underlying the option vested on January 2, 2026. Thereafter, 1/48th of the shares underlying the option will vest monthly, with full vesting scheduled for October 2, 2029, subject to the Reporting Person's continuous service with the Issuer on each such vesting date. Show more

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BridgeBio Oncology Therapeutics Inc

GET /v1/forms/4/0001193125-26-003027 API docs